Key Financial Data Of Group

TORII PHARMACEUTICAL CO., LTD. - Filing #7271627

Concept As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
Key financial data of group
Business results of group
Net sales
60,426,000,000 JPY
54,638,000,000 JPY
48,896,000,000 JPY
46,987,000,000 JPY
41,700,000,000 JPY
Ordinary profit (loss)
6,926,000,000 JPY
5,307,000,000 JPY
5,537,000,000 JPY
4,847,000,000 JPY
4,971,000,000 JPY
Net assets
121,533,000,000 JPY
120,134,000,000 JPY
119,224,000,000 JPY
117,015,000,000 JPY
115,091,000,000 JPY
Total assets
140,664,000,000 JPY
133,432,000,000 JPY
133,689,000,000 JPY
130,810,000,000 JPY
126,026,000,000 JPY
Net assets per share
4,323.33
4,274.45
4,243.08
4,165.38
4,097.55
Basic earnings (loss) per share
179.38
146.60
140.39
120.13
124.47
Diluted earnings per share
124.46
Equity-to-asset ratio
0.864 xbrli:pure
0.900 xbrli:pure
0.892 xbrli:pure
0.895 xbrli:pure
0.913 xbrli:pure
Rate of return on equity
0.042 xbrli:pure
0.034 xbrli:pure
0.033 xbrli:pure
0.029 xbrli:pure
0.031 xbrli:pure
Price-earnings ratio
26.3 xbrli:pure
24.3 xbrli:pure
20.8 xbrli:pure
24.0 xbrli:pure
25.9 xbrli:pure
Net cash provided by (used in) operating activities
3,639,000,000 JPY
-3,123,000,000 JPY
2,420,000,000 JPY
-156,000,000 JPY
-3,443,000,000 JPY
Net cash provided by (used in) investing activities
-3,571,000,000 JPY
-3,779,000,000 JPY
-13,676,000,000 JPY
-1,498,000,000 JPY
7,625,000,000 JPY
Net cash provided by (used in) financing activities
-3,944,000,000 JPY
-3,835,000,000 JPY
-1,698,000,000 JPY
-1,546,000,000 JPY
-1,425,000,000 JPY
Cash and cash equivalents
30,805,000,000 JPY
34,681,000,000 JPY
45,420,000,000 JPY
58,374,000,000 JPY
61,576,000,000 JPY
Number of employees
592 xbrli:pure
592 xbrli:pure
583 xbrli:pure
563 xbrli:pure
560 xbrli:pure
568 xbrli:pure
Average number of temporary employees
53 xbrli:pure
53 xbrli:pure
43 xbrli:pure
34 xbrli:pure
25 xbrli:pure
51 xbrli:pure

Talk to a Data Expert

Have a question? We'll get back to you promptly.